IMMUNIZATIONS – Adds to existing law to establish a moratorium on certain uses of human gene therapy products.
Summary
S1346 would create a two-year temporary moratorium in Idaho on administering certain human gene therapy products for infectious disease indications to children under 18 and to pregnant women. The bill states that the restriction applies regardless of how the product is delivered or described, including if it is called an immunization, vaccine, or something else. It also exempts human gene therapy products used to treat cancer or genetic disorders.
The measure includes a process for an individual product to be exempted from the moratorium after legislative review of safety data, informed consent procedures, and assurances regarding compensation for adverse outcomes. The stated purpose is to allow time for additional safety data to be reviewed before these products are used in the covered populations.
Impact
If enacted, the bill would add a new section to Chapter 48, Title 39 of the Idaho Code and temporarily restrict the use of certain gene therapy products in specific populations. It would affect providers, manufacturers, and patients by limiting administration to minors and pregnant women for infectious disease uses, while leaving cancer and genetic-disorder treatments outside the moratorium. The bill also creates a legislative review pathway for product-specific exemptions and is described as having no anticipated fiscal impact to the General Fund.
Sentiment
The available context suggests the bill is being advanced by its sponsors as a precautionary public health measure focused on safety review and informed consent. The bill’s last recorded action was recommittal to the Health & Welfare committee, and there are no recorded votes or committee transcripts provided here to show broader debate. Overall, the sentiment in the supplied materials appears procedural and cautious rather than clearly supportive or oppositional, with the bill still under committee consideration.
Contention
The main point of contention is likely whether Idaho should impose a blanket temporary restriction on certain gene therapy products for infectious disease use in children and pregnant women before additional safety data is available. Supporters appear to emphasize caution, review of adverse-outcome protections, and the ability to exempt specific products after legislative scrutiny. Potential opponents would likely focus on access to medical products, the breadth of the moratorium, and whether the bill could be seen as treating vaccines or other immunizations differently depending on terminology or delivery method.